#Announcing FDA has granted Geneseeq’s multi-cancer early detection solution, CanScan™, as Breakthrough Device Designation! . Read more about CanScan™: #NGS #oncology #cancer #Geneseeq #FDA

#Announcing the National Medical Products Administration (#NMPA) has approved the Geneseeq Non-Small Cell Lung Cancer Tumor Mutational Burden (NSCLC TMB) Testing Kit!. Read more about the NSCLC TMB Test Kit: #NGS #oncology #cancer #Geneseeq

#Announcing the CE-markings of our multi-cancer early detection kit and multi-cancer minimal residual disease kit! . #cemark #MCED #MRD.

Our early cancer detection test displays high performance in differentiating early lung cancer patients from healthy individuals, and detecting Stage I lung cancers and tumors < 10mm! Learn more below. @atscommunity #earlycancerdetection #lungcancer .

RT @idtdna: TODAY at #ASHG22! . Haimeng Tang from @GeneseeqInc will give a presentation titled “ctDNA for minimal residual disease research….

A new oral presentation at #NCAM we worked on that assesses the efficacy and safety of osimertinib in #NSCLC patients with a sensitizing #EGFR mutation and T790M mutations, who have progressed following prior treatment with an approved EGFR #TKI.

Happy to announce our partnership with Brazilian hospital Hospital de Base to build an #NGS cancer genomics lab in-house! .#cancertesting .

An overview of our high-performing early cancer detection program. #precisiononcology #earlydetection.

Excited to be back at #ASCO22? We participated in the science behind 7 posters and 1 oral this year. Read more below and see you in Chicago! #precisiononcology .

A study using our comprehensive gene panel Geneseeqprime, provides an overview of kinase IGRs in a large #lungcancer cohort and examines real-world survival outcomes of patients.

Our DECIPHER study on #livercancer early detection was published in @HEP_Journal. The study demonstrates excellent performance in early #cancerscreening for liver cancer population while distinguishing ICC from HCC, using #liquidbiopsy.

Our DECIPHER early cancer detection program published a study in the @AASLDFoundation Hepatology journal on detecting liver cancer early. In the study, the liver cancer screening tests demonstrated high sensitivity and specificity. #Cancer #earlydetection.

The study was conducted to demonstrate the status of perioperative ctDNA positivity is significantly associated with disease recurrence and long-term patient outcomes for resectable #NSCLC.

A recent study we worked on shows that #ctDNA surveillance shows to predict tumor relapse earlier than traditional medical images with a lead time of 8.71 months!.#liquidbiopsy .

Read about our newest study on using our comprehensive gene panel to characterize insightful tumor biomarkers and guide personalized adjuvant treatment for non-small-cell lung cancer patients! .@NaturePortfolio .#cancerresearch #NSCLC .

Geneseeq and collaborators published a study on the genomic landscape of metastatic lung adenocarcinomas from clinical sequencing data of over 6000 samples!.#CancerResearch.

Geneseeq and collaborators published a study with the largest early-stage colorectal cancer (stage 0/1) study cohort on #earlydetection. The study yielded encouraging results!. Read more about the study below:.

Our new study on repair-associated DNA polymerases in a cohort of 12,266 patients across 16 different tumor types demonstrates pathogenicity and additive prognostic value of polymerase and DDR pathway gene alterations. #cancerresearch #geneseeq

Geneseeq will be presenting the results of a multi-center prospective study on the dynamic monitoring of ctDNA in children’s lymphoma at #SIOP2021!. Follow the conference for more details.

We are excited to announce our strategic collaboration with @ZaiLab_Global to advance cancer care in bringing products through the R&D cycle further, and faster. #cancercare #precisiononcology.